Overweight Clinical Trial
— FBT for T1DOfficial title:
A Family-Based Approach to Treat Obesity and Its Co-morbidities in Youth With Type 1 Diabetes (T1D) and Their Parents
Type 1 Diabetes carries high burden for affected youth and their families. Advances in insulin therapy and technology have been associated with increased obesity with 1/3 adolescents being overweight/obese. Since obesity runs in families and carries risk for poor outcomes psychologically and medically, the investigators are adapting our successful evidence-based Family Based Treatment for hybrid delivery to improve obesity and metabolic control in the affected youth and improve obesity and related co-morbidities in their parents.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: - T1D of 12 or more months duration - Age 6-17-years - Presence of overweight/obesity - Youth uses a pump for insulin delivery and a continuous glucose monitoring device to monitor glycemic levels - Youth has one parent with overweight/obesity willing to participate in the program Exclusion Criteria: - Child: - Chronic conditions other than T1D - Other autoimmune conditions other then T1D or autoimmune thyroiditis. - Medications that can affects weight, such as medications used to treat Attention Deficit Disorder or high dose steroids used to treat asthma. - Depression symptoms by standard of care Patient Health Questionnaire (PHQ) 9 in the child or parent - Inability to perform at least mild physical activity such as walking - Child with handicap (such as developmental delay or deafness) that would prevent him/her from benefitting from counseling in person and/or remotely Participating parent with - symptoms of depression assessed by standard of care PHQ - autoimmune disorders other than T1D or autoimmune thyroiditis - Participating parents with chronic disorder that is treated with medications that interfere with weight loss or are preventing him/her from performing at least mild physical activity |
Country | Name | City | State |
---|---|---|---|
United States | Conventus | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York at Buffalo | National Center for Advancing Translational Sciences (NCATS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Weight for parent and child | Participants will be given Body Trace Weight Scales and will weigh themselves twice per week. | Baseline, 3 and 6 months | |
Secondary | Change in insulin dosing | Metrics will be obtained through Insulin pumps | baseline, 3 and 6 months | |
Secondary | In parents, change in severity of obesity co-morbidities | Participants will be given Body Trace Weight Scales and will weigh themselves twice per week. Parent co-morbidities will be tracked on a sheet | baseline, 3 and 6 months | |
Secondary | Change in HbA1c | Metrics will be obtained through Continuous Glucose Monitor | baseline, 3 and 6 months | |
Secondary | Change in time in range (TIR) - that is in optimal glycemic range | Metrics will be obtained through Continuous Glucose Monitor | baseline, 3 and 6 months | |
Secondary | In parents, change in medication dosing | Parent medications will be tracked on a sheet. | baseline, 3 and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02899390 -
Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes
|
N/A |